Shigenori Ei
Overview
Explore the profile of Shigenori Ei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
An J, Kurilov R, Peccerella T, Bergmann F, Edderkaoui M, Lim A, et al.
Transl Oncol
. 2024 Sep;
49:102109.
PMID: 39217851
Background: Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve...
2.
Mashiko T, Carreras J, Ogasawara T, Masuoka Y, Ei S, Takahashi S, et al.
Surgery
. 2024 May;
176(2):259-266.
PMID: 38796389
Background: This single-center retrospective study aimed to clarify the clinical and pathologic background of mass-forming intrahepatic cholangiocarcinomas. Methods: A total of 53 patients with mass-forming intrahepatic cholangiocarcinomas were selected from...
3.
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, et al.
Nat Cancer
. 2023 Sep;
4(9):1362-1381.
PMID: 37679568
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performed RNA sequencing...
4.
Ei S, Takahashi S, Ogasawara T, Mashiko T, Masuoka Y, Nakagohri T
Gut Liver
. 2023 Feb;
17(5):698-710.
PMID: 36843421
Resection is the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Although the outcome of technically resectable PDAC has improved with advances in surgery and adjuvant therapy, the 5-year survival...
5.
Nakagohri T, Takahashi S, Ei S, Masuoka Y, Mashiko T, Ogasawara T, et al.
World J Surg
. 2023 Feb;
47(4):1034-1041.
PMID: 36735046
Background: A positive ductal margin is strongly associated with poor survival in patients with distal cholangiocarcinoma. However, the significance of the radial margin status and its effect on survival are...
6.
Mashiko T, Ogasawara T, Masuoka Y, Ei S, Takahashi S, Mori M, et al.
BMC Surg
. 2022 Dec;
22(1):423.
PMID: 36503431
Background: To evaluate the effectiveness of surgery for recurrent distal cholangiocarcinoma and determine surgical indications based on prognostic factors for the recurrence of distal cholangiocarcinoma. Methods: We analysed the outcomes...
7.
Mashiko T, Ogasawara T, Masuoka Y, Ei S, Takahashi S, Hirabayashi K, et al.
World J Surg
. 2022 Nov;
47(3):729-739.
PMID: 36357802
Background: The prognostic impact of positive peritoneal lavage cytology on pancreatic cancer is unclear. Therefore, this study aimed to evaluate its impact in resectable pancreatic body and tail cancer. Methods:...
8.
Tanaka M, Heckler M, Mihaljevic A, Ei S, Klaiber U, Heger U, et al.
Ann Surg Oncol
. 2022 Sep;
30(4):2401-2408.
PMID: 36153440
Background: Effective chemotherapy (CTx) protocols as induction treatment provide increasing opportunities for surgical resection of locally advanced pancreatic cancer (LAPC). Although improved survival after resection of LAPC with CTx has...
9.
Ogasawara T, Mashiko T, Masuoka Y, Ei S, Takahashi S, Kondo Y, et al.
Tokai J Exp Clin Med
. 2022 Sep;
47(3):149-153.
PMID: 36073288
Introduction: Carcinosarcoma of the gallbladder (CSGB) is very rare, accounting for less than 1% of gallbladder malignancies. Therefore, the biological behavior is not well known. We report the case of...
10.
Ei S, Mihaljevic A, Kulu Y, Kaiser J, Hinz U, Buchler M, et al.
HPB (Oxford)
. 2020 Oct;
23(6):921-926.
PMID: 33087306
Background: The feasibility and safety of minimally invasive enucleation (ME) for benign or borderline pancreatic tumors is still unclear. The aim of this study was to compare outcomes between ME...